Distinguished in 5-Alpha Reductase Deficiency

Tomonobu Hasegawa

Kashiwa, JP 
Distinguished in 5-Alpha Reductase Deficiency
Kashiwa, JP 
OverviewLocationsClinical Research

Overview

Tomonobu Hasegawa practices in Kashiwa, Japan. Hasegawa is rated as a Distinguished expert by MediFind in the treatment of 5-Alpha Reductase Deficiency. Their top areas of expertise are Congenital Hypothyroidism, Panhypopituitarism, Hypothyroidism, Hormone Replacement Therapy (HRT), and Orchiectomy.

Their clinical research consists of co-authoring 322 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of 5-Alpha Reductase Deficiency.

Locations

Kashiwa, Japan
Other Locations
Tokyo, 1608582, Japan
Shinjuku, 1608582, Japan
Kobe, Japan
Saitama, Japan
Sakai, 5998531, Japan
Kitasato, Japan
Sapporo, 0608586, Japan
Course Of Advanced Clinical Medicine, Osaka, Japan
Izumisano, Japan
Miemachi, Japan
Keio, Japan
Hongo, 1130033, Japan
Tsu, Japan
Asahi, 5458585, Japan
Kyoto, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)
A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)
Enrollment Status: Terminated
Publish Date: July 25, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

322 Total Publications

Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.
Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.
Journal: Endocrine journal
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hasegawa's expertise for a condition
ConditionClose
View All 20 Distinguished Conditions
View All 33 Advanced Conditions
View All 130 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile